A Combination Therapy In Patients With Social Anxiety Disorder

This study has been completed.
Information provided by:
ClinicalTrials.gov Identifier:
First received: August 29, 2005
Last updated: October 15, 2008
Last verified: October 2008
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of Vestipitant and Paroxetine in patients with Social Anxiety Disorder (SAD)

Condition Intervention Phase
Social Anxiety Disorder
Drug: vestipitant/paroxetine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD)

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change in score on a Social Anxiety Disorder rating scale following 12 weeks of treatment.

Secondary Outcome Measures:
  • Change in score on a number of rating scales following 12 weeks of treatment assessing symptomatic, behavioural and functional parameters which together provide a more complete description of the disorder.

Estimated Enrollment: 204
Study Start Date: November 2004

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Primary diagnosis of Generalised Social Anxiety Disorder as defined in DSM-IV.
  • Capable of giving informed consent and willing to comply with the study requirements.
  • Women of childbearing potential must agree to one of a number of defined acceptable methods of birth control.

Exclusion criteria:

  • Primary diagnosis within the past 6 months of another Axis 1 disorder such as Major Depression or another anxiety disorder.
  • Use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type.
  • Subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months.
  • Subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening DSM-IV criteria for substance dependence (other than nicotine).
  • Significantly abnormal blood or urine laboratory tests or electrocardiogram (ECG).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00403962

GSK Investigational Site
Hilleroed, Denmark, 3400
GSK Investigational Site
Hvidovre, Denmark, 2650
GSK Investigational Site
Koebenhavn K, Denmark, 1256
GSK Investigational Site
Koebenhavn OE, Denmark, 2100
GSK Investigational Site
Risskov, Denmark, 8240
GSK Investigational Site
Skanderborg, Denmark, 8660
GSK Investigational Site
Soroe, Denmark, 4180
GSK Investigational Site
Huettenberg, Hessen, Germany, 35625
GSK Investigational Site
Achim, Niedersachsen, Germany, 28832
GSK Investigational Site
Berlin, Germany, 10629
GSK Investigational Site
Berlin, Germany, 13053
GSK Investigational Site
Bergen, Norway, N-5068
GSK Investigational Site
Hamar, Norway, N-2317
GSK Investigational Site
Oslo, Norway, 0364
GSK Investigational Site
Sandvika, Norway, 1338
South Africa
GSK Investigational Site
Bloemfontein, South Africa
GSK Investigational Site
Tygerberg, South Africa, 7505
Sponsors and Collaborators
Study Director: GSK Clinical Trials, MD, PhD GlaxoSmithKline
  More Information

Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00403962     History of Changes
Other Study ID Numbers: NKP103401 
Study First Received: August 29, 2005
Last Updated: October 15, 2008
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
South Africa: Medicines Control Council
Norway: Norwegian Medicines Agency
Denmark: Danish Medicines Agency

Keywords provided by GlaxoSmithKline:
Social Anxiety Disorder

Additional relevant MeSH terms:
Anxiety Disorders
Phobic Disorders
Pathologic Processes
Mental Disorders
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Neurokinin-1 Receptor Antagonists

ClinicalTrials.gov processed this record on July 28, 2016